Hemophilia Gene Therapy MarketSize and Trends

Increasing number of hemophilic patients that require treatment and strong product pipeline are expected to drive growth of the hemophilia gene therapy market.

The global hemophilia gene therapy market is estimated to be valued at US$ 330.9 million in 2022 and is expected to exhibit a CAGR of 43.6%% during the forecast period (2022-2030).

Figure 1. Global Hemophilia Gene Therapy Market Share (%), by Hemophilia Type, 2022

Market- Trends

High prevalence of hemophilia is increasing the demand for sustainable treatment of the disease, which is projected to drive the market growth over the forecast period. According to the National Hemophilia Foundation factsheet 2018, hemophilia affected over 400,000 individuals worldwide. Moreover, according to same source, an estimated 75% of patients suffering from hemophilia have no access to treatment or receive inadequate treatment. According to the Centers for Disease Control and Prevention (CDC) report, Hemophilia A occurs in 1 out of 5,000 live male births. It is around four times more common than Hemophilia B. Few effective treatments available for hemophilia require lifetime infusion of expensive drugs manufactured through recombinant biotechnology or from human plasma.

Furthermore, in September 2019, according to the American Journal of Managed Care, the meta-analysis showed that more than 1,125,000 men around the world have the inherited bleeding disorder; 418,000 of those have a severe version of the mostly undiagnosed disease. Previously, only 400,000 people globally were estimated to have hemophilia.

The study found that, per 100,000 males, there are:

1 cases for all severities of hemophilia A
0 cases for severe hemophilia A
8 cases for all severities of hemophilia B
cases for severe hemophilia B

Per 100,000 males, the prevalence at birth is:

6 cases for all severities of hemophilia A
5 cases for severe hemophilia A
0 cases for all severities of hemophilia B
5 cases for severe hemophilia B

For those born with hemophilia, the chances of living a life of normal duration and quality will be reduced by 64% in upper-middle income countries, 77% in middle income, and up to 93% in low income countries. In 2020, the World Federation of Hemophilia (WFH) identified 165,379 people with haemophilia A and 33,076 people with haemophilia B worldwide.

Moreover, according to Center for Disease Control and Prevention, Hemophilia A affects 1 in 5,000 male births and about 400 babies are born with hemophilia A each year. Figure 2. Global Hemophilia Gene Therapy Market Share (%), by Region, 2022